Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).

@article{Bauerschmitz2002AdenoviralGT,
  title={Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).},
  author={Gerd Johannes Bauerschmitz and Shannon D. Barker and Akseli Hemminki},
  journal={International journal of oncology},
  year={2002},
  volume={21 6},
  pages={
          1161-74
        }
}
Gene therapy is an exciting novel approach for treating cancers resistant to currently available modalities. Treatment approaches are based on taking advantage of molecular differences between normal and tumor cells. Various strategies are currently in clinical development, with some promising early results reported with mutation compensation, molecular chemotherapy and replication competent viruses. Adenoviruses are among the most popular vehicles and there is a wealth of clinical data… 

Figures and Tables from this paper

Modified adenoviruses for cancer gene therapy

This review focuses on the various modifications that have been investigated for improving the antitumor effect of adenoviral gene therapy.

Adenoviral vectors for prodrug activation-based gene therapy for cancer.

This review discusses adenoviral vectors and how they can be modified to replicate in a cancer-specific manner and deliver therapeutic genes under multi-tiered regulation to target tumor heterogeneity, including heterogeneity associated with cancer stem cell-like subpopulations.

Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data.

The available preclinical and clinical data on use of oncolytic adenovirus genome can be easily engineered to incorporate different tumor targeting mechanisms and therapeutic transgenes for improved antitumor properties are reviewed.

Current developments in adenovirus-based cancer gene therapy.

Recent developments of Ad-based cancer gene therapy are described, including novel engineering techniques of the Ad capsid for efficient tumor targeting, as well as targeting techniques, to restrict transgene expression to cancer cells.

Tissue-specific promoters for cancer gene therapy

Initial clinical trials have demonstrated the safety and suggested efficacy for TSP-controlled CRADs as a novel approach for cancer gene therapy and proposed methods for controlling crucial viral replication regulators and consequent restriction of replication to tumour cells.

Adenoviruses for treatment of cancer

A discussion of various modifications of adenovirus to achieve efficient anti‐tumor effect is focused on, and special emphasis will be placed on CRAds in multimodality treatments.

Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer

Although they remain in the early stages of basic research, adenovirus-mediated gene therapy and virotherapy are expected to become important therapies for tumors in the future due to their potential targeting strategies.

Recent Progress in Strategies for Adenovirus Mediated Therapeutic Cell Targeting

This review provides a summary of current state-of-the-art techniques to target specifically adenovirus-derived gene delivery vector systems.

Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents

This review summarizes the research done to examine the potency of Ad vectors expressing fusogenic proteins as anti-cancer therapeutics and shows improved spread of Ad-based vectors by expressing exogenous cell-fusion proteins.

Transductional and transcriptional targeting of adenovirus for clinical applications.

Adenovirus targeting is described in the context of improving the safety and efficacy of clinical approaches utilizing adenoviral vectors and replication competent oncolytic agents, suggesting a critical linkage between targeted agents and increases in therapeutic utility.
...

References

SHOWING 1-10 OF 179 REFERENCES

Adenoviruses in oncology: a viable option?

  • A. HemminkiR. Alvarez
  • Medicine, Biology
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 2002
It is suggested that while other vectors could be more useful for treatment of hereditary disease, adenoviruses are highly promising and safe agents for oncology, as suggested in a number of early phase clinical trials.

The development of conditionally replicative adenoviruses for cancer therapy.

  • D. Curiel
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
An advanced understanding of the cancer phenotype, as well as achievements in functionally exploiting viral plasticity, predicate the design and realization of conditionally replicative adenoviral agents with improved characteristics for cancer therapy.

Gene therapy of cancer.

Despite anecdotal reports of therapeutic responses in some patients, unequivocal proof of clinical efficacy is still lacking for most of the varied approaches to gene therapy in humans because of the very low transduction and expression efficiency in vivo of available vectors.

Gene therapy of cancer.

Despite anecdotal reports of therapeutic responses in some patients, unequivocal proof of clinical efficacy is still lacking for most of the varied approaches to gene therapy in humans because of the very low transduction and expression efficiency in vivo of available vectors.

Replicative adenoviruses for cancer therapy

The interplay of the virus with the immune system will likely dictate the success of this approach as a cancer therapy, and capsid modifications are being developed to achieve tumor targeting and enhance infectivity.

In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.

RGDTKSSTR shows antitumor efficacy against ovarian cancer in vivo in animal models and may have the potential to be a useful agent for treating ovarian cancer.

Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer

Results confirm that both the oncolysis caused by a replicating virus and suicide/prodrug gene therapy with HSVtk/GCV have potent antitumor effects and are complementary resulting in a significantly improved treatment outcome.

Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy.

It is demonstrated that the expression of adenoviral receptor is variable among human bladder cancer cells, and this variability may have a significant impact on the outcome ofadenovirus-based gene therapy.

Lentivirus and foamy virus vectors: novel gene therapy tools

A description of available lentiviral vectors, including vector design, applications to disease treatment and safety considerations, and various aspects of the biology of foamy viruses with relevance to vector development are presented.

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy.

The results support the thesis that the three-pronged approach of viral therapy, suicide gene therapy, and radiotherapy may represent a powerful and safe means of selectively destroying tumor cells in vivo.
...